How aggressively should blood pressure be treated in renal transplant recipients?

Current Hypertension Reports

Volumn 2, Issue 5, 2000, Pages 473-477

  Klassen, David K ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

GRAFT SURVIVAL; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE PERIOD; PROTEINURIA; REVIEW;

ANTIHYPERTENSIVE AGENTS; CYCLOSPORINE; GRAFT SURVIVAL; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE PERIOD; PROTEINURIA;

EID: 0034295044     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0030-2     Document Type: Article

References (19)

1. Wolfe RA, Ashby VB, Milford EL, et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341: 1725-1730. An analysis of over 20, 000 patients on the waiting list for renal transplantation that shows that transplantation offers a survival advantage over remaining on dialysis for all age and racial groups.
2. Hariharan S, Johnson CP, Bresnahan BA, et al.: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342: 605-612.
3. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a U. S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of FK506 Kidney Transplant Study Group. Transplantation 1998, 66: 1736-1740.
4. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157: 2413-2445.
5. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995, 123: 754-762.
6. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al.: Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997, 29: 641-650.
7. Klag MJ, Whelton PK, Randall BL, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334: 13-18.
8. Ponticelli C, Montagnino G, Aroldi A, et al.: Hypertension after renal transplantation. Am J Kidney Dis 1993, 21: 73-78.
9. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998, 53: 217-222. An analysis of the European transplant registry that shows that the risk of graft failure was associated with blood pressure. There was no lower limit seen to the graft survival benefits of a lower blood pressure.
10. Sorof JM, Sullivan EK, Tejani A, Portman RJ: Antihypertensive medication and renal allograft failure: a North American pediatric renal transplant cooperative study report. J Am Soc Nephrol 1999, 10: 1324-1330.
11. Cosio FG, Dillon JJ, Falkenhain ME, et al.: Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995, 47: 1 1 3 6-1 1 4 1.
12. Frei U, Schindler R, Wieters D, et al.: Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 1995: 10: 1206-1211.
13. Cheigh JS, Haschemeyer RH, Wang JC, et al.: Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival. Am J Hypertens 1989, 2: 341-348.
14. Vianello A, Mastrosimone S, Calconi G, et al: The role of hypertension as a damaging factor of kidney grafts under cyclosporine therapy. Am J Kidney Dis 1993, 21: 79-83.
15. Mange KC, Cizman B, Joffe M, et al.: Arterial hypertension and renal allograft survival. JAMA 2000, 283: 633-638.
16. Curtis JJ: Treatment of hypertension in renal allograft patients: does drug selection make a difference? Kidney Int Suppl 1997, 63: S75-S77.
17. Stigant CE, Cohen J, Vivera M, Zalzman JS: ACE inhibitors and angiotensin in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000, 35: 58-63. This analysis of 177 renal transplant patients treated with ACE inhibitors and angiotensin II receptor blockers showed these agents not to be associated with change in renal function and to be relatively well tolerated.
18. Hausberg M, Barenbrock M, Hohage H, et al.: ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999, 33: 862-868. A randomized, double-blind study comparing treatment of hypertension with quinapril or atenolol. Patients treated with quinapril had no change in renal function an a decrease in albumen excretion.
19. Del Castillo D, Campistol JM, Guirado L, et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998, 54(suppl 68): S135-S139.